(R)-3-氨基-2,3,4,5-四氢-1H-苯并氮杂-2-酮 | 137036-55-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (R)-3-氨基-2,3,4,5-四氢-1H-苯并氮杂-2-酮
• 英文名称: (R)-3-amino-2,3,4,5-tetrahydro-1H-[1]-benzazepin-2-one
• 英文别名: (R)-3-amino-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one；(3R)-3-amino-1,3,4,5-tetrahydro-1-benzazepin-2-one
• CAS: 137036-55-6
• 化学式: C₁₀H₁₂N₂O
• 分子量: 176.218
• InChiKey: AUAKXRGQXZRTQC-MRVPVSSYSA-N

物化性质

• 沸点：
  377.5±42.0 °C(Predicted)
• 密度：
  1.143±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  (R)-3-氨基-2,3,4,5-四氢-1H-苯并氮杂-2-酮 在 palladium on activated charcoal 氢气 、 sodium hydride 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 25.0 ℃ 、275.79 kPa 条件下， 反应 6.5h， 生成 N-[1-[[(2'-Amino)[1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-t-butoxycarbonylamino-3-methylbutanamide
  参考文献：
  名称：

  一种有效的，口服生物利用的苯并ze庚酮生长激素促分泌素。

  摘要：

  L-739,943（8b）是一种有效的，口服可生物利用的苯并内酰胺生长激素促分泌素的鉴定产品，是通过两性离子L-692,429的氨基酸侧链修饰和酸性2'-四唑的中性和效价增强而获得的2'-（N-甲基氨基羰基氨基）甲基取代基。L-739,943口服活性低至0.5 mg / kg，可在比格犬中释放生长激素。剂量为2 mg / kg时，狗8b的口服生物利用度为24％，平均药物Cmax为145 +/- 46 ng / mL。与原型苯并内酰胺L-692,429相比，L-739,943在效能和口服生物利用度方面均取得了重大突破。

  DOI：

  10.1021/jm970816j
• 作为产物：
  描述：

  1,3,4,5-四氢-2H-1-苯并氮杂卓-2-酮 在 三甲基氯硅烷 、 四甲基乙二胺 、 氨 、 碘 、 sodium iodide 作用下， 以 乙腈 为溶剂， 生成 (R)-3-氨基-2,3,4,5-四氢-1H-苯并氮杂-2-酮
  参考文献：
  名称：

  An efficient asymmetric synthesis of (R)-3-amino-2,3,4,5-tetrahydro-1H-[1]benzazepin-2-one

  摘要：

  Two approaches for the asymmetric preparation of (-)- or (+)- alpha-aminobenzlactam 1 are described. One route is based on the asymmetric hydrogenation of enamide 5 and the other on the racemization/resolution of (+/-)-1.

  DOI：

  10.1016/s0040-4039(00)76874-2

文献信息

• [EN] SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR CCR5 A BASE DE QUINOLEINE SUBSTITUES
  申请人：SCHERING AG

  公开号：WO2004002960A1

  公开（公告）日：2004-01-08

  The present invention relates to CCR5 receptor antagonists of formulae (1a) or (1b), enantiomers, diastereomers, salts and solvates thereof wherein R1, R2, R3, R4, R5, and R7 are as defined herein. The invention further includes a method of CCR5-mediated disorders employing such compounds.

  本发明涉及式（1a）或（1b）的CCR5受体拮抗剂，其对映体、二对映体、盐和溶剂合物，其中R1、R2、R3、R4、R5和R7如本文所定义。该发明还包括一种利用这些化合物治疗CCR5介导的疾病的方法。
• A convergent asymmetric synthesis of a growth hormone secretagogue
  作者：Nan Zheng、Joseph D. Armstrong、Kan K. Eng、Jennifer Keller、Tom Liu、Robert Purick、Joseph Lynch、Frederick W. Hartner、R.P. Volante

  DOI：10.1016/j.tetasy.2003.09.022

  日期：2003.11

  Described herein is a convergent asymmetric synthesis of growth hormone secretagogue (GHS) suitable for large-scale preparations. Key features include: (1) an improved method for α-iodination of a lactam; (2) a novel synthesis of a disubstituted urea using Ti(Oi-Pr)4 and NaBH4; (3) construction of biphenyl ureas via an unprecedented Suzuki coupling; (4) an in situ mesylation/N-alkylation of a benzolactam

  本文描述了适合大规模制备的生长激素促分泌素（GHS）的收敛性不对称合成。主要特征包括：（1）一种改进的内酰胺α-碘化方法；（2）使用Ti（O i -Pr）4和NaBH 4新颖合成二取代尿素；（3）通过史无前例的Suzuki偶联剂构建联苯脲；（4）苯并内酰胺的原位甲磺酸化/ N-烷基化。
• Benzo-fused lactams that promote the release of growth hormone
  申请人：Merck & Co., Inc.

  公开号：US05206235A1

  公开（公告）日：1993-04-27

  There are disclosed certain novel compounds identified as benzo-fused lactams which promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to increase the stature of those afflicted with a lack of a normal secretion of natural growth hormone. Growth promoting compositions containing such benzo-fused lactams as the active ingredient thereof are also disclosed.

  已披露了一些新型化合物，被确定为苯并咪唑内酰胺，可促进人类和动物体内生长激素的释放。这种特性可以用于促进食用动物的生长，使可食用肉制品的生产更加高效，在人类身上，可以增加那些缺乏正常分泌天然生长激素的人的身高。还披露了含有苯并咪唑内酰胺作为活性成分的促生长组合物。
• Benzo-fused lactams promote release of growth hormone
  申请人：Merck & Co., Inc.

  公开号：US05672596A1

  公开（公告）日：1997-09-30

  There are disclosed certain novel compounds identified as benzo-fused lactams which promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to increase the stature of those afflicted with a lack of a normal secretion of natural growth hormone. Growth promoting compositions containing such benzo-fused lactams as the active ingredient therefore are also disclosed.

  已披露了一些新型化合物，被确认为苯并融合内酰胺，可以促进人类和动物体内生长激素的释放。这种特性可用于促进食用动物的生长，使可食用肉制品的生产更加高效，在人类身上，可以增加那些患有正常生长激素分泌缺乏的人的身高。因此，还披露了含有这些苯并融合内酰胺作为活性成分的促进生长的组合物。
• Evaluation of a 125I-labelled benzazepinone derived voltage-gated sodium channel blocker for imaging with SPECT
  作者：Carlos Pérez-Medina、Niral Patel、Mathew Robson、Adam Badar、Mark F. Lythgoe、Erik Årstad

  DOI：10.1039/c2ob26695d

  日期：——

  Voltage-gated sodium channels (VGSCs) are a family of transmembrane proteins that mediate fast neurotransmission, and are integral to sustain physiological conditions and higher cognitive functions. Imaging of VGSCs in vivo holds promise as a tool to elucidate operational functions in the brain and to aid the treatment of a wide range of neurological diseases. To assess the suitability of 1-benzazepin-2-one derived VGSC blockers for imaging, we have prepared a 125I-labelled analogue of BNZA and evaluated the tracer in vivo. In an automated patch-clamp assay, a diastereomeric mixture of the non-radioactive compound blocked the Nav1.2 and Nav1.7 VGSC isoforms with IC50 values of 4.1 ± 1.5 μM and 0.25 ± 0.07 μM, respectively. [3H]BTX displacement studies revealed a three-fold difference in affinity between the two diastereomers. Iodo-destannylation of a tin precursor with iodine-125 afforded the two diastereomerically pure tracers, which were used to assess binding to VGSCs in vivo by comparing their tissue distributions in mice. Whilst the results point to a lack of VGSC binding in vivo, SPECT imaging revealed highly localized uptake in the interscapular region, an area typically associated with brown adipose tissue, which in addition to high metabolic stability of the iodinated tracer, demonstrate the potential of 1-benzazepin-2-ones for in vivo imaging.

  电压门控钠通道（VGSCs）是一类跨膜蛋白，介导快速神经传递，对维持生理条件和更高认知功能至关重要。在活体内成像VGSCs有望作为一种工具，阐明大脑的功能，并有助于治疗多种神经疾病。为了评估衍生自1-苯并氮杂氢化噻吩-2-酮的VGSC封闭剂在成像中的适用性，我们制备了一个标记有125I的BNZA类似物，并在体内评估了该示踪剂。在自动化贴片钳实验中，非放射性化合物的一个消旋体混合物以4.1 ± 1.5 μM和0.25 ± 0.07 μM的IC50值分别阻断Nav1.2和Nav1.7 VGSC亚型。[3H]BTX替代研究显示这两种消旋体之间的亲和力存在三倍差异。使用碘-125对锡前体进行碘脱锡反应得到两种消旋体纯的示踪剂，这两者被用来通过比较它们在小鼠中的组织分布来评估在体内对VGSC的结合。虽然结果显示在体内缺乏VGSC的结合，SPECT成像显示在肩胛间区域的高度局部化摄取，该区域通常与棕色脂肪组织相关，这不仅表明碘化示踪剂具有很高的代谢稳定性，还展示了1-苯并氮杂氢化噻吩-2-酮在活体成像中的潜力。